All companies
Visit website
RS BIOTHERAPEUTICS
OperatingRS Bio Therapeutics, Inc.
Healthcare · Biotech · Founded 2021
Novel solutions for lung diseases
Valuation cap ⓘ
$40.0M
As of Aug 2024 · from RS BioTherapeutics Convertible Note 1 · a SAFE/note conversion ceiling, not a priced valuation
Total raised
$195,154
Across 1 round since 2024
Financials
FY2021–FY2024 · from SEC filings · hover any figure for its source$0
−$1.7M
2021
$0
−$543K
2022
$0
2023
$0
2024
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2021
FY2022
FY2023
FY2024
Income statement
Revenue
$0
$0
$0
$0
Cost of goods sold
$0
$0
$0
$0
Net income
-$1,748,009
-$543,074
$0
$0
Taxes paid
$0
$0
$0
$0
Balance sheet
Cash
$1,502,397
$4,979
$4,779
$14,158
Accounts receivable
$0
$0
$0
$0
Total assets
$1,527,085
$31,300
$31,300
$40,617
Short-term debt
$1,025,615
$1,051,533
$589,895
$589,895
Long-term debt
$24,056
$10,104
$0
$188,555
Total liabilities
$1,049,671
$1,061,637
$589,895
$778,450
Other
Headcount
—
—
5
5
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$40.0M
Valuation cap
RS BioTherapeutics Convertible Note 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $195.2K / $1.2MInvestors 90Valuation cap $40M
Reg CF annual-report compliance
Not requiredFewer than 300 holders of record
Filed 1 of 2 annual reports (FY2024–FY2025)
90 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 9 filings on EDGARSource: ManualCIK 0001932193
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.